Stoke Therapeutics, Inc. (STOK)
NASDAQ: STOK · IEX Real-Time Price · USD
13.50
-0.67 (-4.73%)
At close: Mar 28, 2024, 4:00 PM
12.90
-0.60 (-4.44%)
After-hours: Mar 28, 2024, 7:59 PM EDT

Stoke Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year 2023202220212020201920182017
Revenue
8.7812.4100000
Revenue Growth (YoY)
-29.22%------
Gross Profit
8.7812.4100000
Selling, General & Admin
41.3238.9231.920.8511.914.411.96
Research & Development
82.2377.8454.1732.223.768.373.6
Operating Expenses
123.55116.7686.0753.0435.6812.785.55
Operating Income
-114.77-104.36-86.07-53.04-35.68-12.78-5.55
Interest Expense / Income
-9.91-3.12-0.120.7000
Other Expense / Income
-0.17-0.17-0.14-1.5-3.35-0.260
Pretax Income
-104.7-101.07-85.81-52.24-32.33-12.52-5.56
Net Income
-104.7-101.07-85.81-52.24-32.33-12.52-5.56
Shares Outstanding (Basic)
443937331811
Shares Outstanding (Diluted)
443937331811
Shares Change
13.10%5.87%9.71%86.34%2433.56%5.86%-
EPS (Basic)
-2.38-2.60-2.34-1.56-1.80-17.65-8.29
EPS (Diluted)
-2.38-2.60-2.34-1.56-1.80-17.65-8.29
Free Cash Flow
-82.68-35.83-68.11-43.27-32.69-11.89-5.67
Free Cash Flow Per Share
-1.88-0.92-1.85-1.29-1.82-16.76-8.46
Gross Margin
100.00%100.00%-----
Operating Margin
-1307.21%-841.24%-----
Profit Margin
-1192.47%-814.73%-----
Free Cash Flow Margin
-941.72%-288.82%-----
EBITDA
-109.88-100.65-83.7-49.62-31.88-12.31-5.45
EBITDA Margin
-1251.46%-811.40%-----
Depreciation & Amortization
4.733.542.231.930.450.210.11
EBIT
-114.61-104.19-85.93-51.54-32.33-12.52-5.56
EBIT Margin
-1305.32%-839.90%-----
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).